ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,584.54
      -0.88%
      US Tech 100
      19,673.98
      -2.21%
      Dow Jones
      39,753.75
      0.08%
      Brent Oil
      85.06
      0.01%
      Bitcoin
      57,390.49
      -0.63%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Salarius Pharmaceuticals Inc (SLRX)

      7. Salarius Pharmaceuticals Inc (SLRX) News

      SLRX

      Salarius Pharmaceuticals (SLRX)

      Salarius Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:SLRX
      DateTimeSourceHeadlineSymbolCompany
      12:21PMiHub NewswireFeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
      05/16/20234:34PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      05/16/20234:05PMGlobeNewswire Inc.Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SLRXSalarius Pharmaceuticals Inc
      05/12/20238:00AMGlobeNewswire Inc.Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SLRXSalarius Pharmaceuticals Inc
      05/11/20238:00AMGlobeNewswire Inc.Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
      05/09/20238:00AMGlobeNewswire Inc.FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing SarcomaNASDAQ:SLRXSalarius Pharmaceuticals Inc
      05/01/20238:30AMGlobeNewswire Inc.Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164NASDAQ:SLRXSalarius Pharmaceuticals Inc
      05/01/20238:05AMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      05/01/20238:03AMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      04/20/20238:30AMGlobeNewswire Inc.Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual MeetingNASDAQ:SLRXSalarius Pharmaceuticals Inc
      04/04/20234:02PMGlobeNewswire Inc.Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational ConferenceNASDAQ:SLRXSalarius Pharmaceuticals Inc
      03/27/20238:30AMGlobeNewswire Inc.Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
      03/15/202311:00AMGlobeNewswire Inc.Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual MeetingNASDAQ:SLRXSalarius Pharmaceuticals Inc
      03/13/20238:56AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      03/07/20238:00AMGlobeNewswire Inc.Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone SymposiaNASDAQ:SLRXSalarius Pharmaceuticals Inc
      02/16/20238:30AMGlobeNewswire Inc.Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of TexasNASDAQ:SLRXSalarius Pharmaceuticals Inc
      02/15/20234:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      02/15/20234:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      02/15/20234:02PMEdgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      02/13/20234:31PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      01/27/20238:30AMGlobeNewswire Inc.Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development SummitNASDAQ:SLRXSalarius Pharmaceuticals Inc
      01/19/20238:30AMGlobeNewswire Inc.Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development SummitNASDAQ:SLRXSalarius Pharmaceuticals Inc
      01/10/202311:12AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      01/05/20236:12PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      01/05/20236:09PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      01/05/20236:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      01/05/20235:36PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      01/05/20235:33PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SLRXSalarius Pharmaceuticals Inc
      01/05/20238:00AMGlobeNewswire Inc.Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein DegradersNASDAQ:SLRXSalarius Pharmaceuticals Inc
      12/13/20228:01AMGlobeNewswire Inc.Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual MeetingNASDAQ:SLRXSalarius Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:SLRX

      Your Recent History

      LSE
      CM34
      Citi Fun 23
      Delayed Upgrade Clock